Table II.
The Cancer Genome Atlas molecular subtypes and characteristics of patients with GC.
| Clinicopathological factors | EBV+, n (%) | MSI, n (%) | GS, n (%) | CIN, n (%) | P-value |
|---|---|---|---|---|---|
| Sex | 0.238 | ||||
| Male | 5 (7.7) | 7 (10.8) | 10 (15.4) | 22 (33.8) | |
| Female | 1 (1.5) | 8 (12.3) | 4 (6.2) | 8 (12.3) | |
| Age/year | <0.001 | ||||
| ≤60 | 3 (4.6) | 1 (1.5) | 12 (18.5) | 18 (27.7) | |
| >60 | 3 (4.6) | 14 (21.5) | 2 (3.1) | 12 (18.5) | |
| Tumor location | 0.008 | ||||
| EGJ | 2 (3.1) | 3 (4.6) | 7 (10.8) | 17 (26.2) | |
| Distal stomach | 4 (6.2) | 12 (18.5) | 7 (10.8) | 13 (20.0) | |
| Lauren classification | 0.582 | ||||
| Diffuse | 2 (3.1) | 3 (4.6) | 5 (7.7) | 8 (12.3) | |
| Intestinal | 2 (3.1) | 5 (7.8) | 6 (9.2) | 16 (24.6) | |
| Mixed | 2 (3.1) | 7 (10.8) | 3 (4.6) | 6 (9.2) | |
| Adjuvant therapy | 0.833 | ||||
| XELOX | 3 (4.6) | 7 (10.8) | 6 (9.2) | 17 (26.2) | |
| SOX | 3 (4.6) | 8 (12.3) | 8 (12.3) | 13 (20.0) |
GC, gastric cancer; EBV, Epstein-Barr virus; MSI, microsatellite instability; GS, gene stable; CIN, chromosome instability; EGJ, gastro-esophageal junction; XELOX, capecitabine combined with oxaliplatin; SOX, S1 combined with oxaliplatin.